<p>神经分泌生物科学公司（NASDAQ:NBIX - 获取免费报告）的股票在目前覆盖该股票的 22 位分析师中获得了 “适度买入” 的平均推荐，Marketbeat Ratings 报告称。三位分析师给予该股票持有评级，十九位分析师给予公司买入评级。在过去一年中，对该股票发布评级的券商的平均 12 个月目标价为 162.00 美元。</p>
<p>获取 <strong>Neurocrine Biosciences</strong> 警报：</p>
<ul>
<li>关注的 3 只生物科技股票：Iovance、Neurocrine 和 Viking</li>
</ul>
<p>NBIX 最近成为几份研究报告的主题。BMO 资本市场将神经分泌生物科学的目标价从 96.00 美元上调至 115.00 美元，并在 5 月 6 日的研究报告中给予公司 “市场表现” 评级。HC Wainwright 将神经分泌生物科学的股票目标价从 185.00 美元下调至 168.00 美元，并在 4 月 22 日的报告中给予公司 “买入” 评级。Wedbush 在 5 月 6 日的研究报告中重申了对神经分泌生物科学股票的 “跑赢大盘” 评级。瑞银集团在 5 月 6 日的研究报告中将神经分泌生物科学的目标价从 137.00 美元上调至 152.00 美元，并给予公司 “买入” 评级。最后，Guggenheim 在 5 月 6 日的研究报告中将神经分泌生物科学的目标价从 155.00 美元上调至 165.00 美元，并给予该股票 “买入” 评级。</p>
<p><strong>获取我们最新的神经分泌生物科学股票分析</strong></p>
<h2>内部人士下注</h2>
<ul>
<li>百时美施贵宝的大额收购：在 2 笔生物科技交易中花费 181 亿美元</li>
</ul>
<p>在其他新闻中，董事 Kevin Charles Gorman 在 5 月 27 日的交易中出售了 9,613 股该股票。该股票以平均价格 120.38 美元出售，总价值为 1,157,212.94 美元。出售完成后，该董事在公司持有 514,596 股，价值约为 61,947,066.48 美元。这笔交易代表其持股比例减少了 1.83%。该交易在证券交易委员会的备案中披露，您可以通过此链接访问。此外，董事 William H. Rastetter 在 5 月 5 日的交易中出售了 30,000 股公司的股票。该股票以平均价格 110.20 美元出售，总价值为 3,306,000.00 美元。交易完成后，该董事直接持有 37,491 股公司股票，价值 4,131,508.20 美元。这笔交易代表其持股比例减少了 44.45%。该销售的披露信息可以在这里找到。内部人士在上个季度共出售了价值 7,112,920 美元的 59,975 股公司股票。4.30% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者和对冲基金最近对公司的持仓进行了调整。亨廷顿国家银行在第四季度将其在神经分泌生物科学的持股增加了 73.5%。亨廷顿国家银行现在拥有 229 股公司股票，价值 31,000 美元，此前在上个季度又购买了 97 股。Geneos Wealth Management Inc.在第一季度将其在神经分泌生物科学的持仓增加了 143.6%。Geneos Wealth Management Inc.现在拥有 229 股公司股票，价值 25,000 美元，此前在上个季度又收购了 135 股。GeoWealth Management LLC 在第四季度将其在神经分泌生物科学的持股增加了 65.4%。GeoWealth Management LLC 现在拥有 258 股公司股票，价值 35,000 美元，此前在上个季度又收购了 102 股。WPG Advisers LLC 在第一季度购买了神经分泌生物科学的新头寸，价值约 32,000 美元。最后，Smallwood Wealth Investment Management LLC 在第一季度收购了神经分泌生物科学的新股份，价值约 34,000 美元。目前 92.59% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>神经分泌生物科学股票上涨 0.7%</h2>
<ul>
<li>中型股神经分泌生物科学在第三季度报告后是否值得买入？</li>
</ul>
<p>NASDAQ:NBIX 周三开盘价为 128.74 美元。该公司的市值为 127.4 亿美元，市盈率为 43.64，市盈率增长比为 1.31，贝塔值为 0.24。该公司的 50 日移动平均价格为 122.20 美元，200 日移动平均价格为 121.53 美元。神经分泌生物科学的 12 个月最低价为 84.23 美元，最高价为 157.98 美元。</p>
<p>神经分泌生物科学（NASDAQ:NBIX - 获取免费报告）最近在 5 月 5 日发布了季度收益数据。该公司报告每股收益（EPS）为 0.08 美元，低于市场共识预期的 0.70 美元（差额为 0.62 美元）。该公司在本季度的收入为 5.726 亿美元，而分析师预期为 5.8706 亿美元。神经分泌生物科学的股本回报率为 11.81%，净利润率为 12.68%。该公司本季度的收入同比增长 11.1%。在去年同期，该公司每股收益为 1.20 美元。平均而言，股票研究分析师预测神经分泌生物科学今年的每股收益将达到 4.28 美元。</p>
<h2>关于神经分泌生物科学</h2>
<p>（获取免费报告）</p>
<p>神经分泌生物科学公司在美国和国际上发现、开发和销售用于神经、神经内分泌和神经精神疾病的药物。公司的产品包括用于迟发性运动障碍和亨廷顿舞蹈病相关舞蹈症的 INGREZZA；用于肾上腺功能不全的 ALKINDI；用于经典先天性肾上腺增生的 Efmody 胶囊；用于子宫内膜异位症的 Orilissa 片；以及用于治疗子宫肌瘤的 Oriahnn 胶囊。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非 Neurocrine Biosciences</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>电动车税收抵免即将结束——这两只股票可能会飙升的原因</li>
<li>零售投资者如何交易多伦多证券交易所 (TSX)？</li>
<li>不要错过：3 只蓝筹股将在本财报季大幅上涨</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>亚马逊的 Prime Day 回调遇上看涨的黄金交叉信号</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Neurocrine Biosciences 吗？</h2>
<p>在考虑 Neurocrine Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Neurocrine Biosciences 并不在名单上。</p>
<p>虽然 Neurocrine Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

神经分泌生物科学

<p>神经分泌生物科学公司（NASDAQ:NBIX）获得了 22 位分析师的 “适度买入” 平均推荐。19 位分析师将其评级为买入，3 位分析师评级为持有。12 个月的平均目标价格为 162.00 美元。最近的价格目标包括 BMO 资本市场的 115.00 美元和瑞银集团的 152.00 美元。内部人士最近出售了股票，机构投资者持有 92.59% 的股份。该股票开盘价为 128.74 美元，市值为 127.4 亿美元，市盈率为 43.64</p>

<p>Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have earned an average recommendation of &#34;Moderate Buy&#34; from the twenty-two analysts that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $162.00.</p>
<div class="lb-trans"><p>神经分泌生物科学公司（NASDAQ:NBIX - 获取免费报告）的股票在目前覆盖该股票的 22 位分析师中获得了 “适度买入” 的平均推荐，Marketbeat Ratings 报告称。三位分析师给予该股票持有评级，十九位分析师给予公司买入评级。在过去一年中，对该股票发布评级的券商的平均 12 个月目标价为 162.00 美元。</p>
</div><p>Get <strong>Neurocrine Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Neurocrine Biosciences</strong> 警报：</p>
</div><ul>
<li>3 Biotech Stocks to Watch: Iovance, Neurocrine &amp; Viking</li>
</ul>
<div class="lb-trans"><ul>
<li>关注的 3 只生物科技股票：Iovance、Neurocrine 和 Viking</li>
</ul>
</div><p>NBIX has been the topic of several recent research reports. BMO Capital Markets upped their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a &#34;market perform&#34; rating in a research report on Tuesday, May 6th. HC Wainwright lowered their price target on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, April 22nd. Wedbush reissued an &#34;outperform&#34; rating on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. UBS Group lifted their price objective on Neurocrine Biosciences from $137.00 to $152.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, May 6th. Finally, Guggenheim raised their price target on Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, May 6th.</p>
<div class="lb-trans"><p>NBIX 最近成为几份研究报告的主题。BMO 资本市场将神经分泌生物科学的目标价从 96.00 美元上调至 115.00 美元，并在 5 月 6 日的研究报告中给予公司 “市场表现” 评级。HC Wainwright 将神经分泌生物科学的股票目标价从 185.00 美元下调至 168.00 美元，并在 4 月 22 日的报告中给予公司 “买入” 评级。Wedbush 在 5 月 6 日的研究报告中重申了对神经分泌生物科学股票的 “跑赢大盘” 评级。瑞银集团在 5 月 6 日的研究报告中将神经分泌生物科学的目标价从 137.00 美元上调至 152.00 美元，并给予公司 “买入” 评级。最后，Guggenheim 在 5 月 6 日的研究报告中将神经分泌生物科学的目标价从 155.00 美元上调至 165.00 美元，并给予该股票 “买入” 评级。</p>
</div><p><strong>Get Our Latest Stock Analysis on Neurocrine Biosciences</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的神经分泌生物科学股票分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的大额收购：在 2 笔生物科技交易中花费 181 亿美元</li>
</ul>
</div><p>In other news, Director Kevin Charles Gorman sold 9,613 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the completion of the sale, the director owned 514,596 shares in the company, valued at approximately $61,947,066.48. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $110.20, for a total value of $3,306,000.00. Following the transaction, the director directly owned 37,491 shares in the company, valued at $4,131,508.20. This trade represents a 44.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,975 shares of company stock worth $7,112,920 over the last quarter. 4.30% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Kevin Charles Gorman 在 5 月 27 日的交易中出售了 9,613 股该股票。该股票以平均价格 120.38 美元出售，总价值为 1,157,212.94 美元。出售完成后，该董事在公司持有 514,596 股，价值约为 61,947,066.48 美元。这笔交易代表其持股比例减少了 1.83%。该交易在证券交易委员会的备案中披露，您可以通过此链接访问。此外，董事 William H. Rastetter 在 5 月 5 日的交易中出售了 30,000 股公司的股票。该股票以平均价格 110.20 美元出售，总价值为 3,306,000.00 美元。交易完成后，该董事直接持有 37,491 股公司股票，价值 4,131,508.20 美元。这笔交易代表其持股比例减少了 44.45%。该销售的披露信息可以在这里找到。内部人士在上个季度共出售了价值 7,112,920 美元的 59,975 股公司股票。4.30% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Huntington National Bank lifted its holdings in Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after buying an additional 97 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock worth $25,000 after acquiring an additional 135 shares during the last quarter. GeoWealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 65.4% in the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares in the last quarter. WPG Advisers LLC purchased a new position in Neurocrine Biosciences in the first quarter valued at about $32,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Neurocrine Biosciences during the 1st quarter valued at approximately $34,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对公司的持仓进行了调整。亨廷顿国家银行在第四季度将其在神经分泌生物科学的持股增加了 73.5%。亨廷顿国家银行现在拥有 229 股公司股票，价值 31,000 美元，此前在上个季度又购买了 97 股。Geneos Wealth Management Inc.在第一季度将其在神经分泌生物科学的持仓增加了 143.6%。Geneos Wealth Management Inc.现在拥有 229 股公司股票，价值 25,000 美元，此前在上个季度又收购了 135 股。GeoWealth Management LLC 在第四季度将其在神经分泌生物科学的持股增加了 65.4%。GeoWealth Management LLC 现在拥有 258 股公司股票，价值 35,000 美元，此前在上个季度又收购了 102 股。WPG Advisers LLC 在第一季度购买了神经分泌生物科学的新头寸，价值约 32,000 美元。最后，Smallwood Wealth Investment Management LLC 在第一季度收购了神经分泌生物科学的新股份，价值约 34,000 美元。目前 92.59% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Neurocrine Biosciences Trading Up 0.7%</h2>
<div class="lb-trans"><h2>神经分泌生物科学股票上涨 0.7%</h2>
</div><ul>
<li>Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股神经分泌生物科学在第三季度报告后是否值得买入？</li>
</ul>
</div><p>NASDAQ:NBIX opened at $128.74 on Wednesday. The company has a market capitalization of $12.74 billion, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24. The firm has a 50-day moving average price of $122.20 and a two-hundred day moving average price of $121.53. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $157.98.</p>
<div class="lb-trans"><p>NASDAQ:NBIX 周三开盘价为 128.74 美元。该公司的市值为 127.4 亿美元，市盈率为 43.64，市盈率增长比为 1.31，贝塔值为 0.24。该公司的 50 日移动平均价格为 122.20 美元，200 日移动平均价格为 121.53 美元。神经分泌生物科学的 12 个月最低价为 84.23 美元，最高价为 157.98 美元。</p>
</div><p>Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). The company had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The company's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.20 earnings per share. On average, equities research analysts predict that Neurocrine Biosciences will post 4.28 earnings per share for the current year.</p>
<div class="lb-trans"><p>神经分泌生物科学（NASDAQ:NBIX - 获取免费报告）最近在 5 月 5 日发布了季度收益数据。该公司报告每股收益（EPS）为 0.08 美元，低于市场共识预期的 0.70 美元（差额为 0.62 美元）。该公司在本季度的收入为 5.726 亿美元，而分析师预期为 5.8706 亿美元。神经分泌生物科学的股本回报率为 11.81%，净利润率为 12.68%。该公司本季度的收入同比增长 11.1%。在去年同期，该公司每股收益为 1.20 美元。平均而言，股票研究分析师预测神经分泌生物科学今年的每股收益将达到 4.28 美元。</p>
</div><h2>About Neurocrine Biosciences</h2>
<div class="lb-trans"><h2>关于神经分泌生物科学</h2>
</div><p>(Get Free Report</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.</p>
<div class="lb-trans"><p>神经分泌生物科学公司在美国和国际上发现、开发和销售用于神经、神经内分泌和神经精神疾病的药物。公司的产品包括用于迟发性运动障碍和亨廷顿舞蹈病相关舞蹈症的 INGREZZA；用于肾上腺功能不全的 ALKINDI；用于经典先天性肾上腺增生的 Efmody 胶囊；用于子宫内膜异位症的 Orilissa 片；以及用于治疗子宫肌瘤的 Oriahnn 胶囊。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Neurocrine Biosciences</li>
<li>Why Invest in 5G? How to Invest in 5G Stocks</li>
<li>EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season</li>
<li>Find and Profitably Trade Stocks at 52-Week Lows</li>
<li>Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Neurocrine Biosciences</li>
<li>为什么投资 5G？如何投资 5G 股票</li>
<li>电动车税收抵免即将结束——这两只股票可能会飙升的原因</li>
<li>零售投资者如何交易多伦多证券交易所 (TSX)？</li>
<li>不要错过：3 只蓝筹股将在本财报季大幅上涨</li>
<li>寻找并盈利交易 52 周低点的股票</li>
<li>亚马逊的 Prime Day 回调遇上看涨的黄金交叉信号</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkJJWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NBIX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Neurocrine Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Neurocrine Biosciences 吗？</h2>
</div><p>Before you consider Neurocrine Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Neurocrine Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Neurocrine Biosciences 并不在名单上。</p>
</div><p>While Neurocrine Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Neurocrine Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

神经分泌生物科学公司（NASDAQ:NBIX）被券商给予 “适度买入” 的平均评级